Art. 47a Directive (EU) 2001/83

In forcesince 21 Jul 2011cited 6×
1.

The safety features referred to in point (o) of Article 54 shall not be removed or covered, either fully or partially, unless the following conditions are fulfilled:

(a)

the manufacturing authorisation holder verifies, prior to partly or fully removing or covering those safety features, that the medicinal product concerned is authentic and that it has not been tampered with;

(b)

the manufacturing authorisation holder complies with point (o) of Article 54 by replacing those safety features with safety features which are equivalent as regards the possibility to verify the authenticity, identification and to provide evidence of tampering of the medicinal product. Such replacement shall be conducted without opening the immediate packaging as defined in point 23 of Article 1.

Safety features shall be considered equivalent if they:

(i)

comply with the requirements set out in the delegated acts adopted pursuant to Article 54a(2); and

(ii)

are equally effective in enabling the verification of authenticity and identification of medicinal products and in providing evidence of tampering with medicinal products;

(c)

the replacement of the safety features is conducted in accordance with applicable good manufacturing practice for medicinal products; and

(d)

the replacement of the safety features is subject to supervision by the competent authority.

2.

Manufacturing authorisation holders, including those performing the activities referred to in paragraph 1 of this Article, shall be regarded as producers and therefore held liable for damages in the cases and under the conditions set forth in Directive 85/374/EEC.

  • Regulation (EU) 2016/16116173335Law

    1. Před částečným nebo úplným odstraněním či překrytím ochranných prvků v souladu s článkem 47a směrnice 2001/83/ES výrobce ověří: a) neporušenost prostředku k ověření manipulace s obalem; b) pravost jedinečného …

  • Opinion of Advocate General Szpunar delivered on 13 January 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision

    The parallel trader parties to the disputes in the main proceedings maintain that the new rules on protection against the falsification of medicinal products require, de facto if not de jure, that the medicinal products covered by those …

    13 Jan 2022 · 62020CC0147

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decisioninterprets

    … where the replacement of the anti-tampering device of the original outer packaging, carried out in accordance with Article 47a(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community …

    17 Nov 2022 · 62020CJ0224

  • Opinion of Advocate General Kokott delivered on 30 May 2024. Harley-Davidson Europe Ltd and Neovia Logistics Services International v EuropeDecision

    Rather, it can be assumed that, in accordance with its more frequent use, it is to be understood as exerting influence, often through deception. [By way of illustration, see judgments of 7 December 2010, R (C‑285/09, EU:C:2010:742, …

    30 May 2024 · 62023CC0297

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decisioninterprets

    This request for a preliminary ruling concerns the interpretation of Article 10(2) and Article 15 of Directive (EU) 2015/2436 of the European Parliament and of the Council of 16 December 2015 to approximate the laws of the Member States …

    17 Nov 2022 · 62020CJ0204

  • Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decisioninterprets

    … of the anti-tampering device of the original outer packaging of that medicinal product carried out in accordance with Article 47a(1) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community …

    17 Nov 2022 · 62020CJ0147